Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 14, No 3 (2022)

Articles

KEYNOTE SPEECH

KOTENKO O.N.
Clinical nephrology. 2022;14(3):3-3
pages 3-3 views
pages 6-7 views

Evaluation of humoral response to Gam-Covid-Vac (Sputnik V) vaccination against COVID-19 in patients on hemodialysis and peritoneal dialysis

Shutov E.V., Bolshakov S.A., Kotlyarova G.V., Emelyanova E.B., Sorokoletov S.M., Dolidze D.D.

Abstract

Background. new Coronavirus infection (covid-19) is a highly contagious infectious disease causing 20 to 30% death in patients with chronic kidney disease receiving hemodialysis or peritoneal dialysis. Vaccination as one of the most effective methods of reducing mortality has been given the main place in disease prevention. objective: evaluation of the level of humoral response to gam-covid-vac (Sputnik V) vaccination against covid-19 in patients receiving hemodialysis and peritoneal dialysis compared with healthy individuals. material and methods. the study included 103 dialysis patients, of whom 48 were uninfected before standard vaccination and 55 patients after a new coronavirus infection; 25 and 30 healthy volunteers served as controls, respectively. Humoral response to vaccination was assessed in all subjects by total sars-cov-2 IgG and IgG antibody levels to the receptor-binding domain of the si subunit of the sars-cov-2 protein. seroconversion levels were compared in all groups (patients on hemodialysis, peritoneal dialysis and controls). results. levels of sars-cov-2 IgG were: in hemodialysis patients io.2±2.2 u/ml, peritoneal dialysis patients 9.з±2.9 u/ml and they did not differ statistically significantly between the groups. In the control group, it was significantly higher: 17.37±5.5 u/ml (p<0.05), compared to dialysis patients. IgG level of antibodies to spike (S) protein of coronavirus was 79,9±12,7 bau/ ml in patients on hemodialysis, 80,7±i7,5 bau/ml on peritoneal dialysis. in the control group it was significantly higher: 272,5±17,6 bau/ml (p<0,05). the study of the antibody levels after vaccination in the groups of covid-19 convalescent showed no significant differences between the groups. Conclusions. Patients who had not previously infection of covid-19 and received peritoneal dialysis and hemodialysis had a reduced humoral response to Gam-Covid-Vac (Sputnik V) vaccination compared to controls. This necessitates dynamic monitoring of antibody levels and earlier administration of a booster dose of the vaccine. Patients on dialysis and controls who underwent covid-19 had comparable levels of seroconversion after vaccination.
Clinical nephrology. 2022;14(3):8-14
pages 8-14 views

Cytokine profile and cardiovascular status in patients with chronic kidney disease after covid-19

Zhmurov D.V., Zhmurov V.A., Petrov I.M., Petelina T.I., Gapon L.I., Yaroslavskaya E.I., Petrova Y.A., Zhmurova E.A., Ermakova A.A., Ermakova P.A.

Abstract

Objective. description of the cytokine model of the development of the cardiovascular changes in patients with chronic kidney disease (ckd) after new coronavirus infection. material and methods. clinical follow-up and examination of 150 patients with ckd after covid-19 was carried out. the examination included the determination of the interleukin-1 (IL-d, il-6, il-8, tumor necrosis factor a (TNF-a), transforming growth factor p (Tgfpd, hscrp, d-dimer, fibrinogen, ferritin, natriuretic peptide, cystatin c levels, echocardiography, 24-hour blood pressure monitoring, calculation of the glomerular filtration rate according to the ckd-epi formula. results. an increase in the pro-inflammatory cytokine levels, an increase in the hscrp, d-dimer, fibrinogen, ferritin, natriuretic peptide levels, a change in the structural and functional state of the cardiovascular system (CVS) in patients, especially in the first 3 months after a coronavirus infection, were found. Significant deterioration of the functional state of the kidneys during 3 months of follow-up was not observed in the majority of patients. Conclusion. Patients with ckd after new coronavirus infection require the supervision of a nephrologist and a cardiologist to monitor the functional state of the cardiovascular system and kidneys, as well as for the cardio- and nephroprotective therapy prescription.
Clinical nephrology. 2022;14(3):15-19
pages 15-19 views

Patients receiving renal replacement therapy with hemodialysis and taking nsaids during the covid-19 pandemic

Rebrov A.P., Grigoryeva E.V., Petrov G.S., Polidanov M.A., Kondrashkin I.E., Blokhin I.S., Tyapkina D.A., Boroday A.A.

Abstract

Objective. to study the features of the use of nonsteroidal anti-inflammatory drugs (nsaids) in patients receiving programmed hemodialysis (HD) during the covid-19 pandemic. material and methods. a survey of 196 patients hd was performed. results. more than half of the patients (iio/56%) receiving program hd took nsaids during the previous 6 months, 75.5% patients took nsaids during the last month, of which 27.7% took medications daily. the main reasons for taking nsaids are joint pain, headache. Almost half of the patients (47%) had a new coronavirus infection (NCI), of which 58.7% patients regularly took nsaids, and 28.2% patients - daily during the last month; 53.8% patients among the patients who did not undergo nici regularly took nsaids, and (27.з% - daily during the last month. Conclusion. More than half (56%) of patients receiving program hd often and for a long time take nsaids, despite the use of anticoagulants during hemodialysis. there was a slight increase in the frequency of nsaid intake in patients with covid-19 infection. considering the fact that the use of nsaids in this category of patients is associated with a high risk of complications, the urgent task remains to timely clarify the fact of the patient's use of nsaids, correction of therapy, selection of the safest drugs and their use regimens.
Clinical nephrology. 2022;14(3):20-24
pages 20-24 views

Iga-nephropathy in belarusian cohort. clinical and pathological peculiarities, factors, associated with unfavorable outcome

Komissarov K.S., Krasko O.V., Dmitrieva M.V., Letkovskaja T.A., Lugovskaya M.A., Kalinovskaya Y.I., Pilotovich V.S.

Abstract

Aim. define clinical, morphological features, factors associated with unfavorable outcome and kidney survival of IgA-nephropathy (IgAN) in city Minsk, republic Belarus. material and methods. it was multicenter clinical trial of 291 patients (31±ii years old, 65,6% male) with igan and initial proteinuria 1,0 [0,42-i,80] g/day, gfr 85 [65-102] ml/min, arterial hypertension 47,4%. 90% of the patients were treated with ace inhibitors. results. multivariate regression analysis revealed independent predictors of unfavorable outcome: arterial hypertension (HR=2,8; p=0,04), gfr<0 ml/min (HR=6,8; p=0,001), tubular atrophy and interstitial fibrosis (T) 26-50% (HR=3,0; p=0,015), t>50% (HR=6,6; p=0,001). the composite 5-, 10-year survival without dialysis and 50% decreasing gfr were 75,7±4 and 47,2±6,8%, respectively. Conclusion. Igan has an unfavorable course of disease in republic Belarus.
Clinical nephrology. 2022;14(3):25-33
pages 25-33 views

Non-diabetic glucosuria in patients with primary chronic pyelonephritis

Berdichevsky V.B., Zhmurov V.A., Romanova A.V., Rasulov F.R., Khilkevich S.V., Boldyrev A.L., Gonyaev A.R., Bichenova A.G.

Abstract

Background. Nondiabetic glucosuria is a poorly understood laboratory manifestation of chronic pyelonephritis. Objective. Evaluation of the laboratory and morphological manifestations of non-diabetic glucosuria, combined with tubular erythrocyuria, in patients with primary chronic pyelonephritis. Material and methods. a study of nephrobiopsy specimens in patients with primary chronic pyelonephritis against the background of manifestations of non-diabetic glucosuria combined with tubular erythrocyuria was performed. The analysis was carried out in combination with the determination of the level of morning glycemia, glycated hemoglobin, the intensity of glucosuria and manifestations of the urinary syndrome. results and discussion. The level of morning glycemia and the proportion of erythrocytes with glycated hemoglobin in the blood of healthy individuals and patients with chronic pyelonephritis did not have significant differences, but were accompanied by variously expressed non-diabetic glucosuria. In patients with chronic pyelonephritis, the urinary glucose kevel was statistically higher, which coincided with an increase in the number of cellular and bacterial inclusions in the urinary sediment. In biopsy specimens, along with unchanged blood cells in the lumen of the distal tubules, leached erythrocytes and their degradation products, pas-positive protein casts, epithelium with signs of atrophy were observed; significant thickening of the walls of the tubules with accumulation of bacteria in the lumen and lymphocytic-leukocyte infiltration of the surrounding interstitium was detected. Conclusion. Non-diabetic glucosuria in combination with tubular erythrocyturia may be one of the factors in the formation of primary chronic pyelonephritis.
Clinical nephrology. 2022;14(3):34-38
pages 34-38 views

Prevalence of risk factors for cerebrovascular diseases in patients with end-stage renal disease

Murkamilov I.T., Sabirov I.S., Murkamilova Z.A., Fomin V.V., Sabirova A.I., Yusupov F.A., Kudaibergenova I.O., Maanaev T.I.

Abstract

Background. Currently, there is an increase in the number of patients with both chronic kidney disease (ckd) and cerebrovascular disease (CVD). patients with cvd that occur secondary to ckd make up a large proportion of patients being followed-up by both nephrologists and general practitioners. the article presents the results of studies conducted with participation of 356 patients with end-stage renal disease. Objective. Evaluation if the prevalence and clinical and functional features of risk factors for cerebrovascular complications in patients with end-stage renal disease. material and methods. 195 men and 161 women with signs of end-stage renal disease were examined. the mean age of the subjects was 57.5 years (minimum - 18 years and maximum - 87 years). As cerebrovascular risk factors, the frequency of cardiac arrhythmias, lipid metabolism disorders, obesity, carotid atherosclerosis, left atrial (la) dilatation, left ventricular hypertrophy (LVH), chronic heart failure (HF), anemia, hyperuricemia, hyperphosphatemia, hypercholesterolemia, dyslipidemia, hypertriglyceridemia, and proteinuria were assessed. in addition, acute-phase blood protein levels were studied. the renal failure severity was assessed based on the serum creatinine and cystatin c levels. the ckd stages were determined by the glomerular filtration rate, which was calculated using the serum cystatin с level. results. in patients with end-stage renal disease, the prevalence of cvd was 17.4%. in the structure of cvd, the most common type was chronic cerebral ischemia - 91.9%, the frequency of ischemic and hemorrhagic strokes was 29.0 and 11.2%, respectively. in terms of gender, the frequency of occurrence of various types of cvd was higher among females. the prevalence of lipid metabolism disorders was 55.8%. la dilatation was recorded in 39.6% of patients. the prevalence of lvh and left ventricular systolic dysfunction was 71.6 and 11.2%, respectively. remodeling of the carotid arteries was noted in 52.5% of the examined patients with end-stage renal disease. in the structure of "renal risk factors" for cerebrovascular disorders, hyperuricemia (48.8%), proteinuria (42.6%), anemia (36.2%) and hyperphosphatemia (23.o%) were common. the prevalence of hypercholesterolemia, dyslipidemia, and hypertriglyceridemia was 35.9%, 33.1, and 31.7%, respectively. an increase in blood fibrinogen level was detected in 23.o% of patients. an increase in circulating platelets in the peripheral blood was noted in 12.6% of cases, and elevated blood с-reactive protein level was recorded in 23.8% of patients. Conclusion. In end-stage renal disease, the most common risk factors for the development of cvd are lvh (71.6%), lipid metabolism disorders (55.8%), carotid artery remodeling (52.5%), hyperuricemia (48.8%), proteinuria ( 42.6%), anemia (36.2%), hypercholesterolemia (35.9%), dyslipidemia (33.i%), and hypertriglyceridemia (31.7%).
Clinical nephrology. 2022;14(3):39-51
pages 39-51 views

Kidney damage in patients with chf and obesity (local register data)

Mikhailova Z.D., Omarova Y.V.

Abstract

Aim. To study the effect of obesity on the clinical and laboratory status of patients with chf depending on polymorbidity and the variant of kidney damage. material and methods. The study included 176 patients with chf aged 69.48±13.24 years. patients were divided into 2 groups: the main - 78 patients with obesity I-III degree and the comparison group - 98 (normal or overweight). venous blood was taken from all patients on the 1st-3rd day of hospitalization in order to determine the levels of creatinine, ngal, cystatin c, nt-probnp, st2 and their content was assessed depending on the presence and severity of obesity, the variant of kidney damage, and polymorbidity. results. in the studied sample, 44.32% of patients had obesity of i-iii degrees. every 2nd patient was diagnosed with obesity of the 1st degree, and almost every 3rd patient was diagnosed with obesity of the 2nd degree. 43.59% of patients with obesity had сз-5 ckd prior to the present hospitalization. in 37.18% of patients with obesity, proteinuria was determined, mainly of subnephrotic level. aki was diagnosed in every 5th patient (23.29%), in patients with obesity mainly (63.16%) of 2-з stages. during hospitalization, 2.84% of patients died. all the deceased developed aki stage 2 or з in the background of сз-5 ckd. patients with aki had higher levels of all studied biomarkers (ngal, cystatin c, nt-probnp, st2). according to our data, the presence of obesity is associated with the risk of developing aki (OR=2.269, 95% ci o.04-129.799) and the severity of aki (0R=1.246, 95% CI 0.459-3.386), THE FREQUENCY OF HOSPITALIZATION due to the development of ADHF (0R = 1.52, 95% ci o.666- 3.472). Conclusion. Timely diagnosis and treatment of obesity will reduce the risk of aki and mortality, development and progression OF ckd.
Clinical nephrology. 2022;14(3):52-57
pages 52-57 views

Impaired sleep-wakefulness and quality of life in patients with arterial hypertension and chronic kidney disease

Osipov E.V., Batyushin M.M., Nalgieva Z.M.

Abstract

Objective. determination of the effect of impaired sleep-wakefulness on quality of life (QoL) indicators in patients suffering from arterial hypertension (ah) and chronic kidney disease (ckd). material and methods. 55 patients including 20 (36.4%) men and 35 (63.6%) women with documented arterial hypertension and ckd were randomized in the study. to assess the sleep quality (SQ), the Pittsburgh qs index (PSQi); the Athens insomnia scale (Ais) were used; qol was assessed using the sf-36 questionnaire. results. most of the study participants showed a decrease in sq and an impaired sleep-wakefulness. this leads to a decrease in qol in patients with arterial hypertension and ckd. Impaired sleep-wakefulness in patients of this group most pronouncedly affect such criteria for assessing quality of life as physical functioning, pain intensity, mental health, and especially life activity. Conclusion. Violation of the sleep quality was inherent in the majority of the examined. Impaired sleep-wakefulness leads to a decrease in qol in patients suffering from arterial hypertension and ckd.
Clinical nephrology. 2022;14(3):58-63
pages 58-63 views

Laparoscopic resection of a kidney graft with a tumor, our experience

Trushkin R.N., Artyukhina L.Y., Kantimerov D.F., Isaev T.K., Shcheglov N.E., Shevtsov O.S., Klementieva T.M.

Abstract

Background. kidney transplantation is currently the "gold standard” for the treatment of patients with end-stage renal disease (ESRD). kidney transplant patients have two-fold increased risk of developing neoplasms compared to the general population. despite the low incidence of transplanted kidney cancer (0.5%), patients in this group require a non-standard approach from clinicians and represent difficult clinical cases. in particular, complications of the treatment of such patients, except for ordinary ones, include an increased likelihood of purulent-septic complications against the background of constant immunosuppressive therapy. material and methods. we performed laparoscopic resection of a transplanted kidney in 12 patients in our clinic in over 3 years. these formations were detected during screening ultrasound of the kidney graft and in ll cases were asymptomatic, only in l case with a 10x9x8.5 cm tumor, the disease manifested as graft dysfunction and an increase in creatinine levels. results. all patients underwent laparoscopic resection of the transplanted kidney. no bleedings or deaths were registered. Conclusion. thus, laparoscopic resection of a transplanted kidney is an effective method for treating such a rare disease as a transplanted kidney cancer; it allows to reduce the mean bed-day, minimize purulent complications, taking into account minimally invasive technologies. it is also worth noting the encouraging oncological prognosis of these patients; the latter statement requires further follow-up of the operated patients.
Clinical nephrology. 2022;14(3):64-67
pages 64-67 views

Laparoscopic resection of a transplanted kidney with a large tumor

Trushkin R.N., Artyukhina L.Y., Kantimerov D.F., Isaev T.K., Shcheglov N.E., Shevtsov O.S., Klementieva T.M.

Abstract

Given the large number of patients with ESRD, kidney transplantation is currently the only effective treatment for this condition. The kidney transplant population has two-fold increased risk of developing neoplasms compared to non-transplant population. modern methods of treating transplanted kidney tumors do not differ from the methods of treating cancer of non-transplanted kidneys. The recurrence rate after organ-sparing surgery is similar to the recurrence rate in the general population. Histologically, transplanted kidney cancer is represented by both clear cell carcinoma (45.7%) and papillary renal cellcarcinima (42.1%), chromophobic kidney cancer represents 3% and other types of cancer account for 9.1% of cases. The treatment of transplanted kidney cancer includes the same methods as in the treatment of non-transpated kidney cancer: resection of the transplanted kidney, radical nephrectomy, percutaneous radiofrequency ablation of the kidney graft, and percutaneous graft cryoablation. despite the wide possibilities for the treatment of transplanted kidney cancer, there is a large percentage of patients with recurrence of both end-stage renal disease and kidney cancer, which indicates the absence of a proven treatment algorithm and provides an opportunity for a creative approach to the problem of transplanted kidney cancer. given the ambiguity of the problem of transplanted kidney cancer, we would like to represent a clinical case of treating a large, up to 100 mm, tumor of kidney graft with good oncological and functional results. despite the fact that the incidence of renal cell carcinoma in patients with a transplanted kidney is only o.19-o.5%, this clinical case is difficult for urologists.
Clinical nephrology. 2022;14(3):68-71
pages 68-71 views

Choice of surgical approach for removal of a non-functioning kidney graft

Trushkin R.N., Artyukhina L.Y., Shcheglov N.E., Kantimerov D.F., Isaev T.K., Shevtsov O.S., Klementieva T.M., Kolesnikov N.O.

Abstract

The choice of optimal and safe surgical approach is one of the main factors influencing the outcome of graftectomy. The high frequency of intra- and postoperative complications of open graftectomy techniques has led to the development of new safe minimally invasive techniques for removing the kidney graft. one of the new safe methods for removing a non-functioning kidney graft is subcapsular laparoscopic graftectomy. The use of this technique improves the results of surgical treatment of patients with a non-functioning graft.
Clinical nephrology. 2022;14(3):72-76
pages 72-76 views

Prostanorm®: application and effectiveness of use in patients with ureteral stent catheter

Rusanova E.V., Vasilenk I.A., Bychkova N.V., Erofeeva S.B., Schelkova V.V., Voskoboynikova A.K., Kolkhir V.K.

Abstract

Objective: to evaluate clinical efficacy of the herbal medicine prostanorm® in patients with urolithiasis and ureteric catheter-stent implantations after endoscopic radiology operations. materials and methods: 40 female patients with urolithiasis and ureteral stent catheters were enrolled in the prospective study after endoscopic X-ray endourologic surgery (contact ureterolithotripsy (cult)). The dynamics of a number of clinical and laboratory parameters was estimated after prescription of phytopreparation Prostanorm® in the form of monotherapy in a continuous mode with the duration of use of 1 month. results: against the background of the treatment after stent removal (2 weeks from the beginning of the study) as compared to the control group a decrease of micturation frequency by 30% on the average - 6,0±i,8, regression of erythrocyturia and leukocyturia was noted. One month after treatment had begun bacteriological examination of urine showed absence of microbial growth in 25% of cases. Conclusions: prostanorm® has a good antibacterial effect and can be recommended for long-term treatment and prophylactic therapy in patients with catheter-associated urinary infection.
Clinical nephrology. 2022;14(3):77-82
pages 77-82 views

On the importance of continuity of scientific heritage in medicine in general and in nephrology in particular

Bratchikov O.I., Zhilyaeva Y.A., Maksimov V.A.

Abstract

The transfer of scientific heritage between generations of physicians, the preservation and enhancement of the experience of successful methods of professors of the Russian-Soviet school on the example of tissue therapy in the treatment of consequences of coronovirus infection with kidney damage. Acute renal failure (ARF) accompanies up to 20% of cases of infection with a new coronavirus infection and is one of the main risk factors for mortality. The role of polypeptide therapy for the rehabilitation of post-covid renal complications.
Clinical nephrology. 2022;14(3):83-85
pages 83-85 views

The scientific legacy of professor g.a. zakharin (1829-1897) - A GREAT CLINICIAN AND TEACHER. on the 125th anniversary of the scientist's death

Morgoshiya T.S., Inkin A.V.

Abstract

The main scientific and practical achievements of the great Russian therapist and clinician G.a. Zakharin are presented. The little-known facts from the life of Grigory Antonovich as a teacher and a competent clinician are analyzed. it is noted that the medical activity of Grigory Antonovich Zakharin was of great importance for the development of Russian and world clinical thought. he introduced the concept of the body as an integral system, advocating the introduction of prevention and hygiene in medicine. a clinical method created by the joint efforts of Russian doctors of the xviii and early xix centuries and brought by g.a. zakharin, as the prominent french clinician a. yushar said, to the height of art, became the property of doctors all over the world. For 35 years (1861-1896), G.a. Zakharyin was at the head of the faculty therapeutic clinic of Moscow University, steadily observing the method of individualization in his own clinical activity and tirelessly promoting it among his students-students and doctors. Undoubtedly, in the person of G.a. Zakhariina is a venerable figure of an original Russian scientist, deeply erudite, with broad views on the theory of medicine, the personality of a talented diagnostician and empiricist therapist, who completely subordinated his interests to the tasks of recognizing and treating an individual patient.
Clinical nephrology. 2022;14(3):86-92
pages 86-92 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies